Abstract | BACKGROUND: METHODS: We consecutively enrolled the R/M HNSCC patients treated with concurrent PD-1 inhibitor and chemoradiotherapy from August 2018 to April 2022 in Sichuan Cancer hospital. All the patients received the combination of PD-1 inhibitor and chemotherapy, and followed with synergy of concurrent PD-1 inhibitor and chemoradiotherapy, then maintenance PD-1 inhibitor. ORR and DCR was calculated by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST-1.1), and Common terminology criteria for adverse events (CTCAE-4.0) was used to evaluate the toxicity.The Kaplan-Meier method was used to analyze OS and PFS. RESULTS: 40 R/M HNSCC patients were enrolled in our stuty. The median follow up time was 14 months. 22 patients had recurrent disease only, 16 patients had metastatic disease only, and 2 patients had both recurrence and metastasis disease. For the recurrent lesions, 23 patients received a median radiation dose of 64 Gy (range 50-70 Gy). 18 patients received a median dose of 45 Gy (range 30-66 Gy) for metastatic lesions. The median courses of PD-1 inhibitors and chemotherapy were 8 and 5 respectively. After the treatment, the ORR and DCR were 70.0% and 100%. The median OS was 19 months (range 6.3-31.7 months), with 1 and 2-years OS rates of 72.8% and 33.3%. The median PFS was 9 months (range 3.1-14.9 months), with 6 and 12 months PFS rates of 75.5% and 41.4% respectively. The PFS had no statistical significance in PD-L1 negative and positive group (7 vs 12 months, p = 0.059). The most common grade 3 or 4 adverse events(AE) were leucopenia (25.0%), neutropenia (17.5%), anemia (10.0%), thrombocytopenia (5.0%), hyponatremia (2.5%), and pneumonia(2.5%). No grade 5 AE was observed. CONCLUSIONS:
|
Authors | Lu Li, Lu Chen, Lu Yan, Yueqian Guo, Fang Li, Ming Fan, Mei Lan, Xin Lai, Jie Zhou, Yecai Huang, Peng Xu, Jinyi Lang, Mei Feng |
Journal | Radiation oncology (London, England)
(Radiat Oncol)
Vol. 18
Issue 1
Pg. 109
(Jul 04 2023)
ISSN: 1748-717X [Electronic] England |
PMID | 37403098
(Publication Type: Journal Article)
|
Copyright | © 2023. The Author(s). |
Chemical References |
- Programmed Cell Death 1 Receptor
- Immune Checkpoint Inhibitors
- Antineoplastic Agents, Immunological
|
Topics |
- Humans
- Squamous Cell Carcinoma of Head and Neck
(drug therapy)
- Programmed Cell Death 1 Receptor
- Immune Checkpoint Inhibitors
(therapeutic use)
- Antineoplastic Agents, Immunological
(therapeutic use)
- Neoplasm Recurrence, Local
(etiology)
- Head and Neck Neoplasms
(drug therapy)
- Chemoradiotherapy
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Apoptosis
|